The Pathway to Driving Valuation for Your Laboratory: Your Roadmap to Achieving Success, and How to Sustain Growth Despite a Changing Lab Environment
Regardless of whether your lab is in a buying or selling mode—or just preparing for what the future may hold—this timely webinar will provide you with the essential insights you need to increase revenue and operating margin, and effectively maximize your laboratory’s value!
Laboratory Certification and Accreditation: The Joint Commission, COLA Discuss the Most Common Deficiencies and How Labs Should Prepare for Coming Changes
This webinar is the second of a two-part series. Compliance with CLIA and other regulations is getting tougher and more complex. Many labs report that assessments and CLIA inspections of their labs are becoming more rigorous, which has sent them scrambling to respond to the unexpected deficiencies identified during these inspections. Featuring accreditation experts from The Joint Commission and COLA, you’ll hear about their organizations’ list of the Top 10 Deficiencies identified during lab assessments over the past year, and how to prepare your clinical lab stay up-to-date with the latest developments!
Laboratory Certification and Accreditation: CAP & A2LA Discuss the Most Common Deficiencies and How Labs Should Prepare for Coming
Compliance with CLIA and other regulations is getting tougher and more complex. Many labs report that assessments and CLIA inspections of their labs are becoming more rigorous, which has sent them scrambling to respond to the unexpected deficiencies identified during these inspections.
To help CLIA-certified clinical laboratories stay up-to-date with the latest developments, Dark Daily is presenting two special webinars that will give participants access to representatives from all four primary accrediting bodies with deeming authority from CMS to accredit clinical laboratories to the requirements of CLIA.
This webinar, part one of the two-part series, features accreditation experts from the CAP and A2LA. Hear their organization’s list of the Top 10 Deficiencies identified during lab assessments over the past year, and how to prepare your lab!
Newly-Available Medicare Utilization and Price Data for Pathology: Why It’s Important to your Lab and How to Use it to Boost Revenue and Pathologist Compensation
This is a must-attend session for every pathologist and practice administrator! It deals with the reality of today’s tough marketplace for pathology services and will deliver the knowledge you need to help your lab preserve revenue, enhance pathologist income, and expand market share.
- Best strategies on how other pathology practices are dealing with payer prior-authorization programs, successful navigation of payer audits, and managing narrow networks
- An update you’ll want to hear regarding how payers are beginning to institute policies that restrict or totally deny the ability of urologists, GIs, and others to operate an anatomic pathology lab in their practice and get paid for those claims
- Relevant policy/reimbursement/coverage changes within federal Medicare and certain state Medicaid programs that are important for you to know and respond to
- How your pathology lab can develop a strategy for justifying its fair share under new bundled payment arrangements
- How the Medicare utilization/payment data now will allow you to set a competitive fee schedule and demonstrate the “usual and customary” aspect by identifying how much pathology groups in your city/state are charging, and using that data to establish fair prices with your hospital
- How to expand your network status with multiple payers using Medicare utilization/payment data
- Pricing strategies in order to win patients with transparent, competitive prices and how to leverage the Medicare utilization/payment data to position your group as the best value in lab testing
- Plus – to be revealed — the price range, low-to-high, for AP services in 8-10 different regions of the U.S. This is data that has never been available before now, and will prove to be a revelation for you!
Using Diagnostic Management Teams to Add Value with Clinical Laboratory Tests and Pathologists’ Expertise
Diagnostic Management Teams are gaining respect as an effective way for pathologists and clinical laboratory leaders to engage clinicians in ways that directly improve patient outcomes while avoiding unnecessary costs. Best of all, such teams are an effective way for medical laboratories to contribute value as reimbursement shifts to global payment, capitation, or other forms of value-based remuneration to providers. The power of a diagnostic management team (DMT) comes from the fact that it is organized specifically to improve the diagnostic accuracy of a specific disease or health condition. Each DMT brings together pathologists, other lab experts, and physicians with clinical expertise in that field to interpret patient-specific test results in a precise clinical context that includes relevant data in that patient’s medical record. Interest in DMTs is so high that last year’s first annual Diagnostic Management Team Conference in Galveston, Texas, was completely sold out, with more than 250 attendees from throughout the United States and several foreign countries. Recognizing the high interest, as well as the high value, in DMTs, Dark Daily is presenting a special new webinar.
Tougher Lab Regulations and New Legal Issues in 2018: More Frequent Payer Audits, Problems with Contract Sales Reps, Increased Liability for CLIA Lab Directors, Proficiency Testing Violations, and More
Looking forward into 2018, Medicare Part B clinical laboratory price cuts are not the only big story. Other significant threats can upend your laboratory, such as tougher payer audits with higher recovery demands or new federal and state regulatory rules that increase the personal liability of CLIA lab directors and lab executives. The list of regulatory, compliance and managed care threats that must be addressed by clinical labs and pathology group practices in 2018 is lengthy. Each comes with the potential of government sanctions, exclusion from provider networks, large recoupment demands, and greater risk for individual liability of lab directors and lab managers that can include jail time, sizeable fines, and exclusion from federal health programs. As 2018 fast approaches, these are reasons why savvy clinical lab executives, pathologists serving as medical directors of CLIA-licensed labs, and their financial and legal advisors need to come up to speed on the most serious regulatory, compliance, and managed care contracting issues confronting all labs today. Order this webinar now for the critical information you need!
Unique Ways to Partner with Payers to Be Paid for Clinically-Necessary Tests: How to Avoid the Denial Loop
The current insurance reimbursement system for laboratory testing has significant issues, such as decision making that is too far removed from the patient, overprocessing (including dual systems of preauthorization), and tremendous variation between insurance companies regarding medical, administrative, and payment policies. These and other problems lead to conflicts between insurers, health systems and patients. During this all-new webinar, you will get important updates about the current issues plaguing laboratory testing insurance reimbursement systems, and from an expert faculty, learn about specific collaborative strategies that provide potential solutions for your clinical lab.
Primary Diagnosis with Digital Pathology Systems and Whole Slide Images: What Every Pathologist Needs to Know, Why It Will Be Disruptive, and How Innovative Pathology Groups Are Already Making Money with DP
Speedy adoption of digital pathology systems and WSI can give your pathology group considerable competitive advantage. It can mean stronger relationships with referring physicians, more case referrals, expanded market share, increased revenue, and greater pathologist compensation for you and your colleagues. In these financially-stressful times, those are wonderful outcomes and they do help preserve and increase your annual income. That’s why it’s important for you to order this indispensable webinar today!
Deep Medicare Fee Cuts Are Coming to your Clinical Laboratory in 157 Days: What You Must Do Now, Why Congress Might Intervene, and Action Steps to Protect Your Lab’s Financial Integrity
The Centers for Medicare & Medicaid Services are preparing to implement deep cuts to the Part B Clinical Laboratory Test Fee Schedule. Those cuts happen on January 1, 2018. During this webinar, Lâle White of XIFIN will share the findings from her company’s analysis of the 300 million lab test claims that they process each year. This is the actual private payer price data XIFIN’s clients reported to CMS earlier this year. White will help you understand how CMS will use this data to cut the prices for specific tests, along with how your lab can model its test mix to predict how the lab fee cuts will lower your lab’s revenue next year. Next, Julie Scott Allen, who represents NILA, will give you an up-to-the-minute report on how the clinical lab profession is negotiating with CMS to moderate the coming lab fee cuts. She will also provide you with an update on issues in Congress that affect clinical laboratories, including efforts by leading elected officials to change how CMS is preparing to use the PAMA rule to cut Part B lab test fees.
Simple, Swift Approaches to Lab Test Utilization Management: Proven Ways for Your Clinical Laboratory to Use Data and Collaborations to Add Value
Lab test utilization is probably the number one topic in the clinical lab industry today, and this important webinar has much to teach. Get the firsthand insights your lab needs to provide care pathways that improve test utilization, and to identify the right elements to measure so as to demonstrate improved patient care and ultimately lower the overall cost of care.
Preparing Your Lab Company or Hospital for Big Changes in Revenue Recognition Standards and Audits by Your CPA Firm
There’s a major challenge about to confront every public and private lab company that prepares its financial statements according to generally-accepted accounting principles (GAAP). It is the substantial change in revenue recognition standards and this change may cause a measurable downward adjustment in your lab company’s reported financial results. This is the first webinar learning opportunity that explores the requirements of FASB ASC 606-Revenue Recognition Standard as it applies to clinical laboratory companies, diagnostic firms, and other types of molecular, genetic, and pharmacogenetics testing enterprises. The requirement becomes effective on a rolling timeline that starts in 2017. Many lab company executives and their accounting teams have yet to take necessary steps to comply with the new requirements of Rule 606. There are also a substantial number of lab executives whose private lab company follows GAAP in their financial reporting, but who remain unaware of the new requirements of Rule 606. Don’t be one of the lab executives to make a costly mistake—failure to comply in a timely manner can have major consequences—learn more about this indispensable webinar!
Delivering Patient-Centered Lab Testing Services: Elevating the Lab Order with Patient-Centric Repository and New Informatics Tools to Increase Lab Revenue and Support Clinicians for Better Clinical Outcomes
It’s now possible for your medical laboratory to increase revenue specifically because your lab helps physicians achieve better patient outcomes! This is great news particularly if your lab is seeking ways to offset price cuts and shrinking budgets. The secret is to offer patient-centric lab testing services. Great news is that becoming a patient-centric laboratory is not complicated, nor is it time-consuming. Each step forward in becoming a patient-centered lab can generate substantial amounts of new revenue. Learn more about this webinar, and gain indispensable insights to help you implement this powerful trend that can contribute not only to greater revenue, but also to improved reimbursements at your lab.
What Molecular and Genetic Testing Labs Need to Know to Succeed with Commercialization of Their Precision Medicine Products
Confronted with shrinking budgets and falling revenue, lab managers are doing the rational thing by putting more resources into cutting costs, improving staff productivity, and reducing errors. But many approaches to reducing a lab’s cost are band-aids—temporary ‘solutions’ to deeper problems that cost the lab big dollars, and which go unrecognized and unmeasured. Find out what may not be working in your lab, and hear from the experts the secrets of delivering high quality, while achieving significant cost savings!
The Pathway to Driving Valuation for Your Laboratory: Your Roadmap to Achieving Success, and How to Sustain Growth Despite a Changing Lab Environment$245.00
2018 Executive War College Audio Recordings$499.00
Laboratory Certification and Accreditation Part 2: The Joint Commission, COLA Discuss the Most Common Deficiencies and How Labs Should Prepare for Coming Changes$245.00
Laboratory Certification and Accreditation: CAP & A2LA Discuss the Most Common Deficiencies and How Labs Should Prepare for Coming Changes$245.00
Newly-Available Medicare Utilization and Price Data for Pathology: Why It’s Important to your Lab and How to Use it to Boost Revenue and Pathologist Compensation$245.00
Using Diagnostic Management Teams to Add Value with Clinical Laboratory Tests and Pathologists’ Expertise$245.00
2017 Lab Quality Confab Audio Recordings Set$299.00
2017 Lab Quality Confab Audio Recordings – 2 sets$448.00
Tougher Lab Regulations and New Legal Issues in 2018: More Frequent Payer Audits, Problems with Contract Sales Reps, Increased Liability for CLIA Lab Directors, Proficiency Testing Violations, and More$245.00